Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DM3PZLM)

Drug Name	NGR-hTNF DM3PZLM
Synonyms	Arenegyr; NGR-hTNF (solid tumors); Tumor necrosis factor therapy (recombinant protein), MolMed; CD13 TNF-alpha conjugate (solid tumors), MolMed; NGR-hTNF (solid tumors), MolMed; Vascular-targeted TNF (NGR-TNF), MolMed SpA; Vascular-targeted TNF (solid tumors, iv/infusion/biological therapeutic), MolMed

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

2 Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Colorectal cancer	DISNH7P9	2B91.Z	Phase 3	[1]
Malignant pleural mesothelioma	DIST2R60	2C26.0	Phase 3	[2]
------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027311)
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)